التفاصيل البيبلوغرافية
| العنوان: |
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. |
| المؤلفون: |
Gopal, Ajay K.1,2 agopal@u.washington.edu, Kahl, Brad S.3, de Vos, Sven4, Wagner-Johnston, Nina D.5, Schuster, Stephen J.6, Jurczak, Wojciech J.7, Flinn, Ian W.8, Flowers, Christopher R.9, Martin, Peter10, Viardot, Andreas11, Blum, Kristie A.12, Goy, Andre H.13, Davies, Andrew J.14, Zinzani, Pier Luigi15, Dreyling, Martin16, Johnson, Dave17, Miller, Langdon L.17, Holes, Leanne17, Li, Daniel17, Dansey, Roger D.17 |
| المصدر: |
New England Journal of Medicine. 3/13/2014, Vol. 370 Issue 11, p1008-1018. 11p. |
| مصطلحات موضوعية: |
*PHOSPHATIDYLINOSITOL 3-kinases, *LYMPHOMA treatment, *RITUXIMAB, *ALKYLATING agents, *ADVERSE health care events, *THERAPEUTICS |
| مستخلص: |
The article discusses a phase 2 study which explored the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in 125 patients with indolent non-Hodgkin's lymphomas who had not had a response to rituximab and an alkylating agent or had a relapse after such therapies. It cites the anti-tumor activity exhibited by idelalisib with an acceptable safety profile. The most common adverse events of grade 3 or higher are also mentioned. |
| قاعدة البيانات: |
Academic Search Index |
